{
    "eid": "2-s2.0-84890905500",
    "title": "A cost-utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand",
    "cover-date": "2014-01-01",
    "subject-areas": [
        {
            "$": "Rheumatology",
            "@code": "2745"
        },
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        }
    ],
    "keywords": [
        "Azathioprine",
        "Costs and cost analysis",
        "Cyclophosphamide",
        "Decision support techniques",
        "Economic models",
        "Health care rationing",
        "Immunosuppressive agents",
        "Lupus nephritis",
        "Mycophenolic acid",
        "Thailand"
    ],
    "authors": [
        "Adun Mohara"
    ],
    "citedby-count": 14,
    "ref-count": 31,
    "ref-list": [
        "Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden",
        "Lupus in the developing world - is it any different?",
        "Lupus Nephritis in Thailand: Clinicopathologic findings and outcome in 569 patients",
        "J Nephrol Soc Thai",
        "Intravenous cyclophosphamide in lupus nephritis: Twenty years reducing dose",
        "Cyclophosphamide and lupus nephritis: When, how, for how long?",
        "Azathioprine, the Cinderella in the treatment of lupus nephritis",
        "Treatment of severe proliferative lupus nephritis: The current state",
        "Early diagnosis and treatment in lupus nephritis: How we can influence the risk for terminal renal failure",
        "Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: Evidence for coverage decisions in Thailand",
        "Using health technology assessment for informing coverage decisions in Thailand",
        "Handling time in economic evaluation studies.",
        "Analysis of 100 patients with lupus nephritis followed up for 2 years",
        "Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis",
        "Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies",
        "Induction and maintenance therapy for lupus nephritis: A systematic review and meta-analysis",
        "Sequential Therapies for Proliferative Lupus Nephritis",
        "Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis",
        "Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis",
        "EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis",
        "Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial",
        "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis",
        "Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens",
        "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients",
        "The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis",
        "New and future therapies for lupus nephritis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Nontaburi",
            "affilname": "Thailand Ministry of Public Health",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Bureau of Health",
        "Health Technology Assessment Capacity in Thailand",
        "Ministry of Public Health",
        "National Health Security Office, Thailand",
        "Novartis Pharma",
        "Thailand Research Fund"
    ]
}